PGC-1α integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4

Cao,Dedong; Zhou,Hao; Zhao,Jikai; Jin,Lu; Yu,Wen; Yan,Han; Hu,Yu; Guo,Tao

doi:10.3892/or.2014.2974

PGC-1α integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4

Authors:
- Dedong Cao
- Hao Zhou
- Jikai Zhao
- Lu Jin
- Wen Yu
- Han Yan
- Yu Hu
- Tao Guo
View Affiliations

Affiliations: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China
Published online on: January 9, 2014 https://doi.org/10.3892/or.2014.2974
Pages: 1205-1210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) is a key coactivator in the regulation of gene transcriptional activity in normal tissues. However, it is not clear whether it is involved in the angiogenesis and metabolism of multiple myeloma (MM). The aim of the present study was to investigate the role of PGC-1α in MM. Small interfering RNA (siRNA) was used to inhibit PGC-1α expression in RPMI-8226 cells. An endothelial cell migration assay was performed using transwell chambers and the expression of PGC-1α, estrogen-related receptor-α (ERR‑α), vascular endothelial growth factor (VEGF) and glucose transporter-4 (GLUT-4) was tested by reverse transcription-polymerase chain reaction (RT-PCR). The protein expression of PGC-1α, ERR-α and GLUT-4 was assayed by western blot analysis. Lastly, RPMI-8226 cell proliferation was evaluated using CCK-8 assay. VEGF and GLUT-4 mRNA levels were decreased in cells treated with siRNA targeting PGC-1α, as was the level of GLUT-4 protein. Endothelial cell migration was significantly reduced when these cells were cultured with culture medium from RPMI-8226 cells treated with siPGC-1α. The proliferation rates at 24 and 48 h were suppressed by PGC-1α inhibition. Our results showed that inhibition of PGC-1α suppresses cell proliferation probably by downregulation of VEGF and GLUT-4. The present study suggests that PGC-1α integrates angiogenesis and glucose metabolism in myeloma through regulation of VEGF and GLUT-4.

View Figures

View References

1	Munshi NC: Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program. 297:2008.PubMed/NCBI
2	Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M and Vacca A: Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res. 1:76–89. 2011.PubMed/NCBI
3	McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST and Shanmugam M: Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood. 119:4686–4697. 2012. View Article : Google Scholar : PubMed/NCBI
4	Stocks T, Rapp K, Bjorge T, et al: Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 6:e10002012009. View Article : Google Scholar : PubMed/NCBI
5	Vacca A, Ribatti D, Roccaro AM, Frigeri A and Dammacco F: Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol. 28:543–550. 2001. View Article : Google Scholar : PubMed/NCBI
6	Giatromanolaki A, Bai M, Margaritis D, et al: Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res. 30:2831–2836. 2010.PubMed/NCBI
7	Sun CY, Hu Y, Huang J, et al: Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol. 31:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
8	Puigserver P, Wu Z, Park CW, Graves R, Wright M and Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 92:829–839. 1998. View Article : Google Scholar : PubMed/NCBI
9	Handschin C and Spiegelman BM: Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 27:728–735. 2006.
10	Puigserver P and Spiegelman BM: Peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocr Rev. 24:78–90. 2003.
11	Finck BN and Kelly DP: PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 116:615–622. 2006. View Article : Google Scholar : PubMed/NCBI
12	Arany Z, Foo SY, Ma Y, et al: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature. 451:1008–1012. 2008.PubMed/NCBI
13	Lu J, Zhang K, Chen S and Wen W: Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression. Carcinogenesis. 30:636–644. 2009.PubMed/NCBI
14	Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D and Caers J: Biological aspects of angiogenesis in multiple myeloma. Int J Hematol. 94:505–518. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nikhil C and Kenneth C: Advances in Biology and Therapy of Multiple Myeloma. 1. Basic Science. Springer; New York, NY: 2012
16	Adekola K, Rosen ST and Shanmugam M: Glucose transporters in cancer metabolism. Curr Opin Oncol. 24:650–654. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ak I and Gulbas Z: F-18 FDG uptake of bone marrow on PET/CT scan: its correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Ann Hematol. 90:81–87. 2011. View Article : Google Scholar : PubMed/NCBI
18	Bartel TB, Haessler J, Brown TL, et al: F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 114:2068–2076. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kaira K, Endo M, Abe M, et al: Biologic correlation of 2-[¹⁸F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 28:3746–3753. 2010.
20	Podar K and Anderson KC: Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets. 11:1005–1024. 2011. View Article : Google Scholar : PubMed/NCBI
21	Klimcakova E, Chenard V, McGuirk S, et al: PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. Cancer Res. 72:1538–1546. 2012.
22	Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 84:1014–1020. 2004. View Article : Google Scholar : PubMed/NCBI
23	Durie BG, Waxman AD, D’Agnolo A and Williams CM: Whole-body ¹⁸F-FDG PET identifies high-risk myeloma. J Nucl Med. 43:1457–1463. 2002.PubMed/NCBI
24	Zhang K, Lu J, Mori T, et al: Baicalin increases VEGF expression and angiogenesis by activating the ERRα/PGC-1α pathway. Cardiovasc Res. 89:426–435. 2011.PubMed/NCBI
25	Bredella MA, Steinbach L, Caputo G, Segall G and Hawkins R: Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 184:1199–1204. 2005. View Article : Google Scholar : PubMed/NCBI
26	Gendron MC, Schrantz N, Metivier D, et al: Oxidation of pyridine nucleotides during Fas- and ceramide-induced apoptosis in Jurkat cells: correlation with changes in mitochondria, glutathione depletion, intracellular acidification and caspase 3 activation. Biochem J. 353:357–367. 2001. View Article : Google Scholar
27	Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 25:4777–4786. 2006.
28	Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15:1406–1418. 2001. View Article : Google Scholar : PubMed/NCBI
29	DeBerardinis RJ, Mancuso A, Daikhin E, et al: Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 104:19345–19350. 2007. View Article : Google Scholar
30	Zhao Y, Altman BJ, Coloff JL, et al: Glycogen synthase kinase 3α and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol. 27:4328–4339. 2007.
31	Danial NN, Gramm CF, Scorrano L, et al: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 424:952–956. 2003. View Article : Google Scholar
32	Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB: Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 23:7315–7328. 2003. View Article : Google Scholar : PubMed/NCBI
33	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
34	Plas DR and Thompson CB: Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab. 13:75–78. 2002. View Article : Google Scholar : PubMed/NCBI
35	Chang CY and McDonnell DP: Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. Clin Cancer Res. 18:6089–6095. 2012.